Drugs and patents in ATC class L04AE - Sphingosine-1-phosphate (S1P) receptor modulators

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride
GILENYA	fingolimod hydrochloride
TASCENSO ODT	fingolimod lauryl sulfate
ZEPOSIA	ozanimod hydrochloride
MAYZENT	siponimod
SIPONIMOD	siponimod
>Tradename	>Generic Name

Last updated: February 19, 2026

Sphingosine-1-phosphate (S1P) receptor modulators represent a critical class of therapeutics, primarily targeting autoimmune and inflammatory diseases. The patent landscape for L04AE drugs is characterized by a mix of foundational patents, lifecycle management strategies, and emerging intellectual property around novel targets and delivery methods. Market dynamics are shaped by the efficacy and safety profiles of approved agents, the unmet needs in specific disease indications, and the ongoing patent expiries and litigation.

What is the Therapeutic Class L04AE?

The ATC (Anatomical Therapeutic Chemical) classification system designates L04AE as "Sphingosine-1-phosphate (S1P) receptor modulators." These drugs function by binding to and modulating the activity of one or more of the five known S1P receptors (S1P1, S1P2, S1P3, S1P4, and S1P5). S1P receptors are G protein-coupled receptors involved in a wide array of physiological processes, including immune cell trafficking, cardiovascular function, and neuroinflammation. By modulating these receptors, L04AE drugs can reduce the movement of lymphocytes from lymphoid tissues into the central nervous system and other peripheral sites, thereby suppressing immune responses.

What are the Key Approved S1P Receptor Modulators?

The market for S1P receptor modulators includes several approved drugs, each with specific indications and differing pharmacological profiles regarding receptor selectivity.

Fingolimod (Gilenya®): This was the first orally administered S1P receptor modulator approved for relapsing forms of multiple sclerosis (MS). It non-selectively binds to S1P1, S1P3, S1P4, and S1P5 receptors. Its mechanism involves causing the internalization and degradation of S1P1 receptors on lymphocytes, preventing their egress from lymph nodes.
Ozanimod (Zeposia®): Approved for relapsing forms of MS and ulcerative colitis, ozanimod is a selective S1P1 and S1P4 receptor modulator. Its selective binding is designed to reduce the cardiac side effects associated with non-selective modulators.
Siponimod (Mayzent®): Approved for active secondary progressive MS, siponimod is a selective S1P1 and S4 receptor modulator. Its selective profile allows for its use in a broader patient population than some earlier agents.
Ponesimod (Ponvory®): Approved for relapsing forms of MS, ponesimod is a selective S1P1 receptor modulator. It is designed to offer a more targeted approach to immune cell modulation.
Etrasimod (Velsipity®): Approved for ulcerative colitis, etrasimod is a selective S1P1, S1P4, and S1P5 receptor modulator.

Table 1 summarizes key characteristics of approved S1P receptor modulators.

Drug Name	Brand Name	ATC Class	Primary Indications	Receptor Selectivity	Approval Dates (US FDA)
Fingolimod	Gilenya®	L04AE	Relapsing forms of MS	S1P1, S1P3, S1P4, S1P5	2010
Siponimod	Mayzent®	L04AE	Active secondary progressive MS	S1P1, S1P4	2019
Ozanimod	Zeposia®	L04AE	Relapsing forms of MS, Ulcerative Colitis	S1P1, S1P4	2020
Ponesimod	Ponvory®	L04AE	Relapsing forms of MS	S1P1	2021
Etrasimod	Velsipity®	L04AE	Ulcerative Colitis	S1P1, S1P4, S1P5	2022

Source: FDA approvals, company product information.

What is the Patent Landscape for S1P Receptor Modulators?

The patent landscape for S1P receptor modulators is complex, involving composition of matter patents, formulation patents, method of treatment patents, and manufacturing process patents. The initial wave of patents focused on the discovery and synthesis of the first-generation modulators like fingolimod. Subsequent patenting activities have concentrated on:

Second-generation, selective modulators: These patents claim novel chemical entities with improved selectivity for specific S1P receptor subtypes, aiming to reduce side effects and expand therapeutic utility. Examples include patents covering ozanimod, siponimod, ponesimod, and etrasimod.
Formulations and delivery systems: Patents address novel formulations (e.g., extended-release, oral, topical) and delivery devices to improve patient compliance, pharmacokinetic profiles, and drug targeting.
Methods of treatment: Patents claim specific uses of S1P modulators for particular disease indications, patient subgroups, or dosing regimens. This is a common strategy for extending market exclusivity.
Manufacturing processes: Novel synthetic routes or purification methods can also be patented, providing additional layers of protection.

Key patent events and trends:

Fingolimod: The foundational patents for fingolimod have expired in major markets, leading to generic competition. Novartis faced numerous patent challenges and litigations related to Gilenya®. For instance, the key composition of matter patent for fingolimod was set to expire in 2020, with potential extensions. Generic versions have since entered the market.
Ozanimod (Zeposia®): Bristol Myers Squibb's patents for ozanimod cover its composition of matter, methods of use, and formulations. Litigation has arisen from generic manufacturers challenging these patents, particularly focusing on the validity and inventiveness of claims. For example, challenges have targeted patents related to its formulation and specific treatment methods.
Siponimod (Mayzent®): Novartis's patent portfolio for siponimod includes composition of matter and method of treatment patents. Patent expiry dates are critical for the competitive landscape in secondary progressive MS.
Ponesimod (Ponvory®): Johnson & Johnson's patents for ponesimod cover the molecule and its use in treating relapsing MS.
Etrasimod (Velsipity®): Pfizer's (via Arena Pharmaceuticals acquisition) patent strategy for etrasimod includes claims on the molecule, its synthesis, and its application in inflammatory bowel disease.

The average lifespan of a drug patent is 20 years from filing. However, patent term extensions (PTEs) can be granted to compensate for regulatory review delays, effectively extending market exclusivity. The expiration of primary patents for first-in-class molecules often triggers intense litigation as generic companies seek to enter the market.

What are the Market Dynamics and Competitive Landscape?

The market for S1P receptor modulators has witnessed significant growth, driven by the unmet need in autoimmune diseases like multiple sclerosis and inflammatory bowel disease.

Growth drivers:

Efficacy: S1P modulators offer an effective mechanism for reducing disease activity and relapses, particularly in relapsing forms of MS.
Convenience: The availability of oral formulations has improved patient convenience compared to injectable therapies.
Expanding indications: Approval for new indications, such as ulcerative colitis, broadens the patient population and market potential.
Physician and patient familiarity: As more S1P modulators gain approval and market traction, physician and patient awareness and acceptance increase.

Competitive factors:

Safety profile: Side effects, including bradycardia, macular edema, and infections, remain a critical differentiating factor. Newer, more selective agents are designed to mitigate these risks.
Efficacy in specific subtypes: The effectiveness of different modulators across various disease subtypes (e.g., relapsing vs. progressive MS, different inflammatory bowel disease severities) influences prescribing patterns.
Pricing and market access: Reimbursement policies and drug pricing strategies play a crucial role in market penetration.
Patent expiry and generic competition: The expiry of key patents for older S1P modulators opens the door for biosimilar/generic entrants, impacting pricing and market share for originator products. The loss of exclusivity for fingolimod has demonstrated this effect.
Pipeline and novel targets: The ongoing research into new S1P modulators, including those targeting different S1P receptor subtypes or novel mechanisms related to S1P signaling, poses a future competitive threat and opportunity.

The market is segmenting based on receptor selectivity and approved indications. While fingolimod, as a non-selective modulator, pioneered the oral S1P market, newer selective agents are capturing market share by offering differentiated safety and efficacy profiles. The expansion into inflammatory bowel diseases with ozanimod and etrasimod signifies a significant market diversification.

What are the Future Trends and Opportunities?

The future of S1P receptor modulators involves several key trends:

Increased selectivity: Development of agents with even greater selectivity for specific S1P receptor subtypes or distinct signaling pathways downstream of S1P receptors. This aims to further optimize the risk-benefit profile.
Broader therapeutic areas: Research is exploring the role of S1P signaling in other autoimmune, inflammatory, and even neurological conditions beyond MS and IBD, such as rheumatoid arthritis, lupus, and neurodegenerative diseases.
Combination therapies: Investigating the use of S1P modulators in combination with other therapeutic agents to achieve synergistic effects or target multiple disease pathways.
Advanced delivery systems: Development of novel delivery methods, potentially including long-acting injectables or targeted delivery mechanisms, to improve patient adherence and therapeutic outcomes.
Biomarker development: Identifying reliable biomarkers to predict patient response to S1P modulators or monitor disease progression and treatment efficacy.

The patent landscape will continue to evolve with new filings for next-generation molecules, improved formulations, and novel therapeutic applications. Litigation surrounding S1P modulator patents is likely to persist as companies protect their market exclusivity and generic manufacturers challenge existing IP.

Key Takeaways

S1P receptor modulators (L04AE) are a significant class of drugs for autoimmune and inflammatory diseases, with orally administered agents offering convenient treatment options.
The patent landscape is characterized by foundational patents for first-generation drugs and extensive IP around selective modulators, formulations, and methods of treatment.
Patent expiries, particularly for fingolimod, have opened the market to generic competition, influencing pricing and market dynamics.
Market growth is driven by therapeutic efficacy, improved convenience, and expansion into new indications like ulcerative colitis.
Key competitive factors include safety profiles, receptor selectivity, pricing, and the ongoing patent expiry cycle.
Future trends include the development of highly selective modulators, exploration of new therapeutic areas, and advanced drug delivery systems.

Frequently Asked Questions

Which S1P receptor modulators are currently facing significant generic competition? Fingolimod (Gilenya®) is the primary S1P receptor modulator that has experienced substantial generic competition following patent expiries in major markets.
What is the primary driver for the development of selective S1P receptor modulators? The development of selective S1P receptor modulators is driven by the desire to improve the safety profile of these therapies by reducing off-target effects associated with non-selective receptor binding, such as bradycardia and macular edema.
Beyond multiple sclerosis and ulcerative colitis, what other therapeutic areas are being explored for S1P receptor modulators? Research is investigating the potential of S1P receptor modulators in other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and potentially neuroinflammatory conditions beyond MS.
How do patent term extensions (PTEs) impact the market exclusivity of S1P receptor modulators? PTEs can extend the market exclusivity period for S1P receptor modulators beyond the initial 20-year patent term, compensating for delays caused by the regulatory review process. This delays the entry of generic competitors.
What are the main safety concerns associated with S1P receptor modulators, and how are newer agents addressing them? Common safety concerns include a dose-dependent reduction in heart rate (bradycardia), macular edema, increased risk of infections, and potential for liver enzyme elevations. Newer, more selective agents aim to mitigate these risks by targeting specific S1P receptor subtypes known to be more involved in therapeutic efficacy and less involved in adverse cardiovascular or ocular effects.

Citations

[1] Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] European Medicines Agency. (n.d.). European public assessment reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines/qualification-opinion/european-public-assessment-reports-epars [3] World Health Organization. (n.d.). WHO Collaborating Centre for Drug Statistics Methodology. Retrieved from https://www.whocc.no/ [4] National Library of Medicine. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ [5] Various Pharmaceutical Company Investor Relations and Product Information Websites (e.g., Novartis, Bristol Myers Squibb, Johnson & Johnson, Pfizer). (n.d.). [6] United States Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html [7] European Patent Office. (n.d.). Espacenet. Retrieved from https://www.epo.org/searching-for-patents/business/espacenet.html

Drugs in ATC Class L04AE

Drugs in ATC Class: L04AE - Sphingosine-1-phosphate (S1P) receptor modulators

L04AE Sphingosine-1-Phosphate Receptor Modulators: Patent Landscape and Market Dynamics